chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Swollen gland; Low grade fevers; Chills; This is a spontaneous report from a contactable consumer (patient) received via a Pfizer Sponsored Program. A 65-years-old female non-pregnant patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot Number: EN6199), via an unspecified route of administration in the left arm on 08Mar2021 at 13:00 (at the age of 65-years-old) as e dose 1, single for COVID-19 immunization. The most recent COVID-19 vaccine was administered in the health clinic/administration facility. Medical history included ongoing anaphylactic allergy to hornet venom/carry Epi pen, will go into anaphylactic shock without epi pen, from an unknown date and unknown if ongoing. The patient did not receive any other medications within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. It was unknown if, prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Patient stated that since the first shot on 8Mar21, she had experience low grade fevers and chills (no dates, but several days after the first shot, more so like a week after the first shot), off and on since the first shot. She had a low-grade fever last night (25Mar2021), but had not checked her temperature that day (26Mar2021). From 23Mar to present (26Mar), she had a swollen gland on the left side of her throat. Her second shot was scheduled for 29Mar21 and she was wondering if her symptom will interfere with the vaccine response, or if the vaccine will interfere with whatever her immune system was currently responding to (if it was not the first shot that was causing the swollen gland). She was wondering whether, under the current circumstances, she will receive an adverse response to the second shot - or a dangerous response, which makes her concerned whether she should postpone the second shot until after she felt better. She was due for a doctor visit that day (26Mar) to determine cause and treatment. Patient further stated that, the swollen gland has gotten a little better and she was not sure if she needs to actually go in to see the doctor. Patient wanted to ask, how long do side effects last after the first shot. The events resulted in physician office visit. The clinical outcome for the event low grade fevers and chills was not recovered and recovering for swollen gland.  No Follow-up attempts are needed. No further information is expected.
High Fever for two days up to 103, Blurry Vision, Rash all over torso, back, neck, face-Generally acting out of control.
a PENTACEL vaccine was administered, then noted to have expired a few days ago with no reported adverse event; Initial information received on 14-Sep-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 1 years old male patient who was administered a pentacel vaccine , then noted to have expired a few days ago with no reported adverse event ,after receiving vaccine DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL].  The patient's past medical history, medical treatment(s) and family history were not provided. Concomitant medications included MEASLES VACCINE, MUMPS VACCINE, RUBELLA VACCINE (MMR) for Immunisation; HEPATITIS A VACCINE (HEPATITIS A) for Immunisation; PNEUMOCOCCAL VACCINE CONJ (PNEUMOCOCCAL CONJUGATE VACCINE) for Immunisation; and VARICELLA ZOSTER VACCINE (VARICELLA VACCINE) for Immunisation.  On 14-Sep-2022, the patient received a  dose of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE( lot UJ578AAA and expiration date: 10-Sep-2022) at a dose of 0.5ml  via intramuscular route in the right thigh for immunization.   On 14-Sep-2022(latency: same day), the patient was administered a pentacel vaccine , then noted to have expired a few days ago with no reported adverse event (expired product administered) following the administration.   Action taken :not applicable.  It was not reported if the patient received a corrective treatment for the event .   Outcome: unknown   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Pt returned to clinic with raised red area 9cm x 12 cm well defined borders oval in shape, edematous, indurated, (mildly no fluctuation) inflamed warm tender. Diagnosed with cellulitis.
Seizure: while walking, felt weak, nausea, blurred vision, and lost consciousness with observed "jerking movements" of limbs by partner who says she was unresponsive with eyes rolled back into her head. Prior to this reported having aura. In the hours leading up to this, had fever, body aches, chills, nausea. Has history of seizures in childhood and felt this was similar.
On 4/22/21, approximately 1 hr after the Moderna COVID-19 first vaccination injection, I started to encounter allergic reactions that I used to suffer about 20 years ago. My air intake decreased, and my skin began to become irritated. I formerly had environmental allergies that would reduce my air intake, and the first place I noticed the effects were on my skin and I would become irritable. Physicians told me that when my oxygen levels were low, the body would channel the air to where it was most needed, which is generally not the skin, so my skin would become irritated. When this used to occur, I would respond involuntarily with facial twitches and pulling at my face and hair. Physicians explained that these twitches and pulling actions would draw air to the surface of my skin where I was air depleted. When I took the Moderna injection, this happened again -- I found myself with low air, my face was twitching, and I was pulling on my face to draw air to the area. The result when I was 19 and dealing with allergies is that I would remove small patches of hair from my head or eyebrows or eyelashes, and this would happen almost unconsciously as I tried to stimulate the areas and draw air to the surface of my skin. I did the same thing on 4/22/21, and found later, when looking into a mirror, that I had removed a section of my eyebrow unconsciously. It all comes back to oxygen depletion. A different and more intense event occurred in the night of Friday, 4/23/21, and the early morning of Saturday, 4/24/21. I went to bed at about 11 p.m. or 11:30 p.m. Between that time and approximately 1:30 a.m., I had difficulty sleeping, and I dreamed of pain in my chest. I finally woke up about 1:30 a.m. and found the pain in my chest was real. I was having difficulty breathing deeply. It felt as if  the lower part of my lungs (at least on one side) was solidifying or inaccessible. What I did was begin forcing myself to breathe as deeply as possible. Over a period of 30 minutes or longer, I was able to gradually reclaim the use of the deepest part of my longs. With every forced deep breath, I was able to chip away at the area that felt like it was freezing up. Finally, I felt that I could access the deepest part of my longs and breath normally. The pain and lack of use in my lower lungs were very concerning.
Nausea; fluctuated from cold and warm; heavily runny nose; higher than normal blood sugar/going up to three hundred; Chills; warm; This is a spontaneous report from a contactable consumer (patient). A 71-years-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: EN6200), via an unspecified route of administration, administered in left arm on 17Feb2021 13:30 as DOSE 1, SINGLE (at the age of 71-year-old) for covid-19 immunisation. The patient medical history included diabetes. Concomitant medications included clopidogrel (CLOPIDOGREL), gabapentin (GABAPENTIN), hydroxyzine (HYDROXYZINE), insulin (INSULIN), lamotrigine (LAMOTRIGINE) taken from 2021, levothyroxine (LEVOTHYROXINE), lisinopril (LISINOPRIL), and spironolactone (SPIRONOLACTONE). On 18Feb2021, the patient experienced chills, heavily running nose, blood sugar higher than normal after the first dose. It was reported that, nausea started at 04:00 am on 18Feb2021. It stopped sometime when she was sleeping. Chills started in the evening on the day she got the shot. She was warm then. She was busy that day, but she would fluctuated from cold and warm on 18Feb2021. On 18Feb2021, in the morning the patient had heavily runny nose was just dripping. The patient noticed higher than normal blood sugar. She had diabetes and checks her blood sugar. Normally her blood sugar was between 100 and 200. It was going up to three hundred. She was on eye drops, but they don't matter. The patient underwent lab tests which included blood sugar: going up to three hundred on 18Feb2021 (she had higher than normal blood sugar). The seriousness reported as non-serious. Her only question is with the second dose should she expect to have the same side effects or worse or none. Patient did not any AE(s) require a visit to Emergency Room and Physician Office. The outcome of the events nausea, chills, feeling warm and fluctuated from cold and warm were recovered on Feb2021 and heavily runny nose and higher than normal blood was recovering.   No follow-up attempts are possible. No further information is expected.
In the fall of 1997 pt exp fatigue, "brain fog", diffuse musculoskeletal aching, lived reticularis, insomnia, h/a;originally thought to be lyme disease;dx fibromyalgia/chronic fatigue synd or hep b induced polyarteritis like synd;
dizziness; restricted breathing; heart palpitations along with occasional flush feeling; heart palpitations along with occasional flush feeling; very fatigued; This is a spontaneous report from a contactable consumer (patient). A 49-years-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 10Mar2021 at 10:45 (at the age of 49-years-old) as dose 1, single for COVID-19 immunization. Medical history included blood cholesterol increased from an unknown date and unknown if ongoing. Concomitant medication(s) included acetylsalicylic acid (ASPIRIN 81), pravastatin and tadalafil taken for an unspecified indication, start and stop date were not reported. The patient previously took lipitor [atorvastatin] and experienced drug hypersensitivity. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Patient reported that shortly after receiving the shot, 10 Mar2021 11:00, patient experienced dizziness, restricted breathing and heart palpitations along with occasional flush feeling also very fatigued (10Mar2021) and that fatigue continued the next day (today, 11Mar2021). The patient did not receive any treatment. The clinical outcome for the events was recovering except not recovered for very fatigued.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained.
Patient experienced redness, swelling and pain at injection site and sought medication treatment for injection site reaction. Symptoms resolved with ice.
DTaP to left arm 4/27, within 18 hours -> left upper arm shoulder -> Ac redness/edema without cellulitis.
This spontaneous report was received from a pharmacist refers to a 51 year old male patient without drug reactions and allergies. The patient's medical history included unspecified nasal surgery. On 30-MAY-2013 the patient was vaccinated with PNEUMOVAX23 dose 1, intramuscular (lot # was not reported). There were not concomitant medications. On 13-JUN-2014 (also reported as 2 weeks after administration of the PNEUMOVAX23), the patient had titers drawn. He only had "4 markers", rather than 23. Because of this, the patient's physician wanted the patient to have a "booster" dose of PNEUMOVAX23, six weeks after receipt of dose 1. A second dose of the PNEUMOVAX23  had not been administered to the patient at the time of the report. The outcome of patient had titers drawn was unknown. This is one of several reports received from the same source. Additional information has been requested.
Pain, soreness and stiffness in upper arm/shoulder near vaccine site. Pain increased with loss of mobility over the next 72 hours. Treated with pain medication, cortisone injection Dec 6, 2015.
Loss or consciousness about 30 seconds, recovered feeling clammy and ?out of it?  Felt better after reclining and putting feet up
patient developed headache, nausea and abdominal pain day of vaccination that continued for two days post vaccination.
Short after vaccination, the patient complained with blurry vision, nasuea, vomit, then temporarily fainted about 30 seconds.  After 30 seconds, she became conscious, alert , able to communicate. She felt weak and nauseous. She claimed she did not eat that day other than a piece of crackers.  We supplied with water and gatorade; she felt  better but still weak.  Vital was stable at 129/87 and pulse at 92. We asked she wanted to be taken by ambulance but she refused.  She went home with her friend via motor cart.
UTI; feel a little sore; she only had maybe red or warm around the injection site for a couple days; she only had maybe red or warm around the injection site for a couple days; This spontaneous case was reported by a patient and describes the occurrence of URINARY TRACT INFECTION (UTI), PAIN (feel a little sore), VACCINATION SITE WARMTH (she only had maybe red or warm around the injection site for a couple days) and VACCINATION SITE ERYTHEMA (she only had maybe red or warm around the injection site for a couple days) in a 71-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch nos. 055F22B and 069H22A) for COVID-19 prophylaxis.     Concurrent medical conditions included Asthma, Chronic bronchitis, Atrial fibrillation, Blood pressure high, Dust allergy (allergies to stuff in the air), Arthritis (Arthritis - different kinds) and Drug allergy (allergy to narcotics).   On 06-Oct-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 01-May-2023, received sixth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced URINARY TRACT INFECTION (UTI), PAIN (feel a little sore), VACCINATION SITE WARMTH (she only had maybe red or warm around the injection site for a couple days) and VACCINATION SITE ERYTHEMA (she only had maybe red or warm around the injection site for a couple days). The patient was treated with NITROFURANTOIN for UTI, at an unspecified dose and frequency. At the time of the report, URINARY TRACT INFECTION (UTI) and PAIN (feel a little sore) outcome was unknown and VACCINATION SITE WARMTH (she only had maybe red or warm around the injection site for a couple days) and VACCINATION SITE ERYTHEMA (she only had maybe red or warm around the injection site for a couple days) had resolved.            No relevant concomitant medications were reported. Patient received first Moderna dose - 04Mar2021, lot number 029A21A, second dose - 02Apr2021, lot number 017B21A, third dose- 03Dec2021, lot number 033F21A fourth dose - 15Apr2022, lot number 056M21A, fifth dose - 06Oct2022, bivalent lot number 055F22B sixth dose -01May2023, bivalent lot number 069H22A. With all these doses patient experienced only red or warm around the injection site for a couple days and felt a little sore and in "her mind she would call that nothing". The patient received seventh Spikevax dose - 12Oct2023, lot number 203F23A (right arm). She also had flu and Respiratory Syncytial Virus (RSV) vaccines at the same time with the Spikevax but these 2 were administered on her left arm.   This case was linked to MOD-2023-746010 (Patient Link).
After receiving the vaccination I would report that I had the mild reaction of soreness at site of injection.  That soreness became severe on the 4th day after the vaccination.  Today is the 13th day and the pain continues with some weakness in my left arm.  I went back to doctor and reported my symptoms.
Patient received vaccine on 1/19/2021.    5 days later had cold symptoms, chills, loss of taste and smell.   positive COVID test.
Fixed maculopapular rash on chest, abdomen, back, arm and leg.  The rash peaked at day 7. Associated with intense itching.  There is no other IgE mediated reaction.
This spontaneous report as received from a registered nurse refers to a 10 weeks old patient of unknown gender. On 23-JUN-2014 the patient was vaccinated with liquid PEDVAXHIB (lot # J016185, expiry date: 02-OCT-2016, dose and route of administration were not reported) that was exposed to temperatures our of range (multiple excursion over a 24 hour period totaling 5 hours below 36F, including three cycles below 28F, have occurred on unspecified date, reported as prior to the morning of 23-JUN-2014) that were not supported by Merck's stability data. No adverse effects were reported. This is one of several linked reports received from the same reporter. Additional information has been requested.
Malaise and achy and onset of fever of 100F. Was ill for 2 days. Felt like the flu. I received an MMR immunization for work requirements.
This spontaneous report as received from a medical assistant refers to an unspecified number of patients of unknown age and gender. The patients' medical history, concurrent conditions and concomitant medications were not reported. On unknown dates, the patients were vaccinated with the improperly stored (in 51.3 F for 30,75 hours and in 59.4 F for 4,5 hours) doses of RECOMBIVAX HB (lot # M020926, expiration date 11-AUG-2018; dose and route of administration were not reported). No adverse effect and no previous excursion were reported. The call was made because of the data logger. This is one of several reports received from the same reporter. Additional information has been requested.
pt recvd vax & later in evening became very irritable; pt has been extremely irritable to date 20APR; seen by MD 19APR93; hospitalized 3 days dx; Colic (H/O colic) & milk allergy;
pt in hospice facility; tested positive for COVID ON 12/19/21; not eating or drinking; O2 sats 81% on RA; unresponsive; placed on O2 supplementation via NC with O2 sats of 85%; comfort medications; pt's condition continued to deteriorate and she passed away in the hospice facility
This case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a female patient who received TWINRIX adult (batch number HZ9Z9, expiry date 3rd March 2017). Co-suspect products included TWINRIX adult (batch number HZ9Z9, expiry date 3rd March 2017). On an unknown date, the patient received the 1st dose of TWINRIX adult 1 ml. On an unknown date, the dose was an unknown dose. On an unknown date, the patient received the 2nd dose of TWINRIX adult 1 ml. On an unknown date, an unknown time after receiving TWINRIX adult, the patient experienced inappropriate age at vaccine administration. On an unknown date, the outcome of the inappropriate age at vaccine administration was unknown. Additional information: The caller reports that this patient received two doses of the TWINRIX vaccine (have same lot number/expiration date). The patient was 15 years old when they received the vaccine doses (under recommended age for TWINRIX). No other AEs were reported.
I notice a steak of skin turned white on the lower part of my left palm. I had taken a few pictures to document it. I did not feel any adverse sensation. The symptom disappeared when I woke up in the morning.
Ongoing nausea. Difficulty swallowing, fatigue, hypersensitivity, headaches, migraines, dizziness, syncope, abdominal pain, hot flashes, severe weight loss, numbness, burning, tingling, muscle spasms.
Patient had a seizure about 40 seconds after receiving the COVID19 (Pfizer) vaccine. He urinated, and became cyanotic, not breathing and faint pulse. CPR as initiated and 911 called. Patient regained consciousness after 30 compressions and was taken to the hospital after ambulance arrived.
Pt began having bumps appear near injection site then became pruritic then rash and itching.
Client states approx 4 AM on 10/19 she experienced a sore right arm that lasted a few days. Client states she also experienced left leg pain near the knee that was painful to the touch and inflamed. This leg pain continues. No other symptoms reported. Client states she has taken ibuprofen and uses heat for comfort measures. Client states leg pain is a little better but concerned about the continuing leg pain. Advised client to seek care for an assessment from a provider and will contact the client in a few days to assess status. 10/30/23 TC to client. Client states she did not see a provider but that the left leg pain has resolved. No further follow-up.
Upon giving the shot a small knot formed immediately at injection site. Approximately 6 hours later, the knot at injection site was approximately 10" in diameter with redness and heat. Patient reported pain and stiffness of left arm. Instructed patient to take IBU and Benadryl, then contact PCP if not any better the following morning.
Shingrix 2nd dose was due. Should be given IM. Patient received Subcutaneous. Complained of pain, swelling, heat & redness w/bruising over course of 1 day.
This spontaneous report as received form a certified medical assistant refers to a patients of unknown age and gender. The patients' medical history, concurrent conditions and concomitant medications were not reported. On unknown dates, the patients were vaccinated with an unspecified number of doses of improperly stored ROTATEQ orally, lot# M005733 with expiration date: 01-OCT-2017. lot# M018957 with expiration date: 22-OCT-2017, lot# L046318 with expiration date: 28-SEP-2017 and lot# M004544 with expiration date: 18-OCT-2017 (dose was not reported). Administered doses of ROTATEQ underwent a temperature excursion at 9 degrees Celsius for 1 minute. There were no previous excursions. No adverse effects were reported. Product quality complaint (PQC) was not involved. This is one of several reports received from the same reporter. Additional information has been requested.
shortly after receiving the shot I waited 15 minutes. I started not to feel good when I got to my car and went to walk back to get help and pass out. After I got back a nurse or teacher asked me if I was ok and someone went and got help. I was put in a wheelchair my BP or sugar was very low and I was given some snacks.  My boyfriend came and got me. I went to my PCP within the same week.  I was sent to Neurologists within a few weeks because it wasn't the first time I had passed out. I haven't had any follow-ups since When I did have the 2nd shot they had me laying down and they kept me a little longer but I was fine.
SEEN IN ER 12/21/2006. MOM REPORTS DAYCARE REPORTED FEVER OF 106-CHILD TEMP 99.0F(R) DURING TRIAGE. HAD IMMUNIZATIONS 12/20/2006. TYLENOL FOR FEVER. WORK-UP FOR ACUTE FEBRILE ILLNESS.